SAB Biotherapeutics (SABS) FCF Margin (2021 - 2024)
SAB Biotherapeutics (SABS) posted FCF Margin of 8358.96% for Q4 2024, down 183.07% on a QoQ basis from 2952.95% in Q2 2024, and down 392811.0% year-over-year from N/an in Q1 2024.
SAB Biotherapeutics (SABS) FCF Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 8358.96% for Q4 2024.
- Quarterly FCF Margin fell 392811.0% year-over-year to 8358.96% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2618.65% (down 148794.0% YoY) and the FY2024 annual result came in at 2618.65%, down 148794.0% from the prior year.
- FCF Margin was 8358.96% for Q4 2024 at SAB Biotherapeutics, down from 2952.95% in the prior quarter.
- Across five years, FCF Margin topped out at 44.68% in Q1 2021 and bottomed at 8358.96% in Q4 2024.
- A 4-year average of 1592.5% and a median of 222.78% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin sank 567563 bps — and 2024, when it soared 280238 bps.
- SAB Biotherapeutics' FCF Margin stood at 65.47% in 2021, then retreated by 18 bps to 77.41% in 2022, then plunged by 5624 bps to 4430.85% in 2023, then slumped by 89 bps to 8358.96% in 2024.
- Business Quant data shows SABS's FCF Margin at 8358.96% in Q4 2024, 2952.95% in Q2 2024, and 1151.74% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8,358.96% |
| Jun 30, 2024 | -2,952.95% |
| Mar 31, 2024 | -1,151.74% |
| Dec 31, 2023 | -4,430.85% |
| Sep 30, 2023 | -414.49% |
| Jun 30, 2023 | -5,755.33% |
| Mar 31, 2023 | -279.99% |
| Dec 31, 2022 | -77.41% |
| Sep 30, 2022 | -222.78% |
| Jun 30, 2022 | -79.69% |
| Mar 31, 2022 | -92.31% |
| Dec 31, 2021 | -65.47% |
| Sep 30, 2021 | 3.88% |
| Jun 30, 2021 | -54.09% |
| Mar 31, 2021 | 44.68% |